RxDoctor Payments Data

Cynthia Walker

Family · Savoy, ILNPI 1215384573

Payments from drug & device makers

$3,785in general payments, 2019–2025

Across 178 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$596
  • Otsuka America Pharmaceutical, Inc.$588
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$509
  • AbbVie$456
  • Axsome Therapeutics, Inc.$378
  • Johnson & Johnson$249
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$3,75699%
  • Education$291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,785 in reported general payments places this provider in the 90th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$36,728
Medicare patients
37
Services billed
327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate20$72,474
Risperdal ConstaRisperidone Microspheres13$32,129
LybalviOlanzapine/Samidorphan Malate13$22,812
Duloxetine Hcl63$2,266
Bupropion XlBupropion Hcl46$1,696
Oxcarbazepine25$1,314
Mirtazapine34$1,183
Aripiprazole29$1,074
Quetiapine Fumarate75$803
Methylphenidate Hcl23$760
Lamotrigine69$699
Clonazepam59$680
Risperidone56$462
Bupropion Hcl SrBupropion Hcl11$461
Doxepin Hcl18$419

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$249$104,60333 claims
Alkermes, Inc.Lybalvi$596$22,81213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,941 family providers in Illinois.

Other family in Savoy

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →